Get the Stockscreener App
25.88
0.35%
0.09
After Hours:
25.90
0.02
+0.08%
Moderna Inc stock is traded at $25.88, with a volume of 7.51M.
It is up +0.35% in the last 24 hours and down -4.57% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.79
Open:
$25.82
24h Volume:
7.51M
Relative Volume:
0.75
Market Cap:
$10.07B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.9645
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+3.52%
1M Performance:
-4.57%
6M Performance:
-24.26%
1Y Performance:
-59.52%
1-Day Range:
$25.52
$26.23
1-Week Range:
$24.60
$27.10
52-Week Range:
$23.15
$67.96
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.88 | 10.03B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - ACCESS Newswire
Moderna opens new vaccine facility in boost for UK pharmaceutical industry - Yahoo
Moderna: Maintaining Sell Despite ConsolidationAnd Why MRNY Won't Help Either - Seeking Alpha
Voya Investment Management LLC Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study - Stocktwits
Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers - Yahoo Finance
Green defies FDA vaccine rules - Aloha State Daily
Moderna: Updated COVID-19 vaccine generates strong immune response - McKnight's Long-Term Care News
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Des Moines Register
Moderna’s COVID-19 vaccine shows strong response against LP.8.1 variant By Investing.com - Investing.com South Africa
Australia bets on mRNA as Moderna builds regional hub - BioWorld MedTech
Moderna stock rises as Brookline reiterates Buy on strong COVID vaccine data - Investing.com
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows - Benzinga
Moderna's (MRNA) New COVID-19 Vaccine Shows Promising Results in Phase 4 Trial - GuruFocus
Stocks making big moves yesterday: Plug Power, Moderna, Magnite, Compass, and RE/MAX - TradingView
Moderna announces positive prelim immunogenicity data for 2025-2026 formula of mNEXSPIKE - MarketScreener
Moderna updates late-stage trial data for redesigned COVID shot - Seeking Alpha
Moderna Says its 2025-26 COVID-19 Vaccine Appears to Generate Positive Immune Response for LP.8.1 Variant - MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Lelezard
Moderna (MRNA) Shows Promising Results with New COVID-19 Vaccine Formula - GuruFocus
Moderna’s COVID-19 vaccine shows strong response against LP.8.1 variant - Investing.com
Moderna says updated next-generation COVID shot shows strong immune response in patients - Reuters
16x Stronger Immune Response: Moderna's New COVID Vaccine Proves Highly Effective Against Latest Variant - Stock Titan
Sumitomo Mitsui DS Asset Management Company Ltd Sells 26,032 Shares of Moderna, Inc. $MRNA - MarketBeat
Swedbank AB Sells 16,356 Shares of Moderna, Inc. $MRNA - MarketBeat
Inside Biotech: Moderna puts numbers on Australia’s mRNA investment - Proactive financial news
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance
Moderna Inc. Stock Advances 5.2%, Outperforms Peers - 富途牛牛
Moderna Shares Jump After Announcing Q4 2021 Earnings, US$19 Billion Advanced Sales - thedeepdive.ca
Vaccine site could save Australia billions in pandemic - Yahoo News Australia
Rising Leaders 2025: Kerry Benenato Champions The ‘Impossible’ In RNA Therapeutics - insights.citeline.com
Federal government announces that Moderna has started production at its biomanufacturing facility - Canadian Manufacturing
Moderna rises after RFK Jr. vaccine panel’s less-draconian-than-expected Covid recommendation - Sherwood News
Decide on COVID-19 shot at your own peril: ACIP - BioWorld MedTech
Could Moderna’s (MRNA) Index Exit Shift Focus From COVID-19 Hurdles to Pipeline Priorities? - simplywall.st
Moderna, Inc.(NasdaqGS: MRNA) dropped from FTSE All-World Index - MarketScreener
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - The Augusta Chronicle
ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest - insights.citeline.com
Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 6.6%Should You Buy? - MarketBeat
Strs Ohio Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Swedbank AB Lowers Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):